Niraparib Combined With Anlotinib in Homologous Recombination Repair (HRR) Gene-mutated Advanced Solid Tumors
Status: UNKNOWN
Study type: INTERVENTIONAL
Conditions: HER2-negative Breast Cancer|Gastric Adenocarcinoma|Cholangiocarcinoma|Pancreatic Cancer
Interventions: DRUG: Niraparib|DRUG: Anlotinib
Sponsor: Peking University Cancer Hospital & Institute